Condition: Neurotrophic Keratitis · Sponsor: Krystal Biotech, Inc.
The Sponsor is developing KB801, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human nerve growth factor (NGF) to the corneas of people with Stage 2 or 3 neurotrophic keratitis (NK) via topical application. This is a Phase 1/2, multicenter, double-masked, placebo-controlled study to evaluate the safety, tolerability, and preliminary efficacy of KB801 in these subjects.
This description comes directly from the study's public registry record.
David Sweet, MD, PhD · 412-586-5830 · dsweet@krystalbio.com
Brittani Agostini, RN, CCRC · 412-586-5830 · bagostini@krystalbio.com
Always discuss trial participation with your own doctor first.
| UC Irvine Alpha Clinic | Irvine, California, United States | Not Yet Recruiting |
| Azul Vision - California Eye Specialists Medical Group Inc. | Pasadena, California, United States | Recruiting |
| Midwest Cornea Associates | Carmel, Indiana, United States | Recruiting |
| Vance Thompson Vision | Alexandria, Minnesota, United States | Recruiting |
| Minnesota Eye Consultants | Minnetonka, Minnesota, United States | Recruiting |
| St. Louis Eye Institute | Town and Country, Missouri, United States | Recruiting |
| Metropolitan Eye Research and Surgery Institute | Palisades Park, New Jersey, United States | Recruiting |
| Vance Thompson Vision | West Fargo, North Dakota, United States | Recruiting |
| UPMC Vision Institute | Pittsburgh, Pennsylvania, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06999733